extract: 2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk

Pentagon-Agent: Ganymede <F99EBFA6-547B-4096-BEEA-1D59C3E4028A>

domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md

@@ -57,7 +57,7 @@ At net prices with 48% rebates, semaglutide achieves $32,219/QALY ICER, making i
 ### Additional Evidence (challenge)
 *Source: [[2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk]] | Added: 2026-03-16*
 
-Sarcopenic obesity risk from muscle loss + discontinuation may create NEW healthcare costs (falls, fractures, disability care) that offset cardiovascular and metabolic savings, particularly in the Medicare-age population. If the most common outcome is weight cycling with net muscle loss rather than sustained metabolic benefit, the population-level health effect could be negative for elderly patients.
+Sarcopenic obesity risk from GLP-1-induced muscle loss (15-40% of weight lost is lean mass) combined with high discontinuation rates may create NEW healthcare costs that offset cardiovascular and metabolic savings. Elderly patients with sarcopenic obesity face increased fall risk, fractures, and disability—potentially requiring MORE healthcare utilization, not less. This directly challenges the net cost-savings assumption, especially in the Medicare population.
 
 ---
 

domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md

@@ -51,7 +51,7 @@ No data yet on whether payment model affects persistence—does being in an MA p
 ### Additional Evidence (extend)
 *Source: [[2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk]] | Added: 2026-03-16*
 
-The discontinuation problem is compounded by the weight cycling mechanism: patients who stop GLP-1s regain fat preferentially while muscle is NOT regained, creating sarcopenic obesity. This means discontinuation doesn't just eliminate metabolic benefits—it actively worsens body composition relative to baseline, especially in elderly populations already at sarcopenia risk.
+The 64.8% one-year discontinuation rate creates a specific harm mechanism: patients who discontinue regain weight preferentially as fat while muscle lost during treatment is not regained, resulting in sarcopenic obesity with worse body composition than baseline. This weight cycling pattern transforms discontinuation from merely an adherence problem into an iatrogenic risk.
 
 ---
 

entities/entertainment/claynosaurz.md

@@ -23,6 +23,7 @@ Community-driven animated IP founded by former VFX artists from Sony Pictures, A
 - **2025-06-02** — Announced 39-episode × 7-minute CG-animated series co-production with Mediawan Kids & Family, targeting kids 6-12. Distribution strategy: YouTube premiere followed by traditional TV licensing. Community involvement includes sharing storyboards, scripts, and featuring holders' collectibles in episodes. 450M+ views, 200M+ impressions, 530K+ subscribers at announcement.
 
 - **2025-10-01** — Announced 39-episode animated series (7 min each) launching YouTube-first with Method Animation (Mediawan) co-production, followed by TV/streaming sales. Gameloft mobile game in co-development. Community has generated nearly 1B social views. Nic Cabana presented creator-led transmedia strategy at VIEW Conference.
+- **2025-10-01** — Nic Cabana presented at VIEW Conference on creator-led transmedia strategy. Announced 39 x 7-minute animated series co-produced with Method Animation (Mediawan), launching YouTube-first before traditional distribution. Community has generated nearly 1B social views. Gameloft mobile game in co-development. Shared achievement system planned across gaming, social media, collectibles, and community.
 ## Relationship to KB
 
 - Implements [[fanchise management is a stack of increasing fan engagement from content extensions through co-creation and co-ownership]] through specific co-creation mechanisms

entities/internet-finance/futardio.md

@@ -54,7 +54,6 @@ MetaDAO's token launch platform. Implements "unruggable ICOs" — permissionless
 - **2026-02-03** — Hurupay fundraise launched targeting $3M, closed Feb 7 at $2M (67% of target) in refunding status
 - **2026-03-05** — Seyf AI-native wallet launch: raised $200 against $300,000 target, refunded (99.93% shortfall)
 - **2026-03-06** — LobsterFutarchy launch raised $1,183 against $500,000 target, closed in refunding status after one day
-- **2024-08-28** — MetaDAO futarchy proposal to develop futardio (memecoin launchpad with futarchy governance) failed. Proposal would have allocated $100k grant over 6 months to development team. Market rejected the concept, likely due to reputational concerns about associating futarchy with memecoins.
 ## Competitive Position
 - **Unique mechanism**: Only launch platform with futarchy-governed accountability and treasury return guarantees
 - **vs pump.fun**: pump.fun is memecoin launch (zero accountability, pure speculation). Futardio is ownership coin launch (futarchy governance, treasury enforcement). Different categories despite both being "launch platforms."

inbox/archive/.extraction-debug/2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk.json

@@ -1,7 +1,7 @@
 {
   "rejected_claims": [
     {
-      "filename": "glp-1-induced-muscle-loss-combined-with-high-discontinuation-creates-sarcopenic-obesity-trap.md",
+      "filename": "glp-1-induced-muscle-loss-combined-with-high-discontinuation-creates-sarcopenic-obesity-risk.md",
       "issues": [
         "missing_attribution_extractor"
       ]
@@ -10,15 +10,13 @@
   "validation_stats": {
     "total": 1,
     "kept": 0,
-    "fixed": 3,
+    "fixed": 1,
     "rejected": 1,
     "fixes_applied": [
-      "glp-1-induced-muscle-loss-combined-with-high-discontinuation-creates-sarcopenic-obesity-trap.md:set_created:2026-03-16",
-      "glp-1-induced-muscle-loss-combined-with-high-discontinuation-creates-sarcopenic-obesity-trap.md:stripped_wiki_link:glp-1-persistence-drops-to-15-percent-at-two-years-for-non-d",
-      "glp-1-induced-muscle-loss-combined-with-high-discontinuation-creates-sarcopenic-obesity-trap.md:stripped_wiki_link:GLP-1 receptor agonists are the largest therapeutic category"
+      "glp-1-induced-muscle-loss-combined-with-high-discontinuation-creates-sarcopenic-obesity-risk.md:set_created:2026-03-16"
     ],
     "rejections": [
-      "glp-1-induced-muscle-loss-combined-with-high-discontinuation-creates-sarcopenic-obesity-trap.md:missing_attribution_extractor"
+      "glp-1-induced-muscle-loss-combined-with-high-discontinuation-creates-sarcopenic-obesity-risk.md:missing_attribution_extractor"
     ]
   },
   "model": "anthropic/claude-sonnet-4.5",

inbox/archive/2025-07-01-sarcopenia-glp1-muscle-loss-elderly-risk.md

@@ -12,7 +12,7 @@ priority: medium
 tags: [glp-1, sarcopenia, muscle-loss, elderly, safety, lean-mass]
 processed_by: vida
 processed_date: 2026-03-16
-enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md"]
+enrichments_applied: ["glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"]
 extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
@@ -57,9 +57,8 @@ flagged_for_astra: ["GLP-1-induced muscle loss in elderly has parallels to space
 
 
 ## Key Facts
-- 15-40% of total weight lost on GLP-1s is lean body mass (not fat)
-- Some analyses suggest up to 60% lean mass loss in certain patients
 - Natural aging reduces skeletal muscle mass by 12-16%
-- Sarcopenic obesity prevalence: 10-20% of older adults
-- 64.8% of GLP-1 patients discontinue within 1 year
-- Next-generation GLP-1 therapies aim to improve muscle preservation per ADA
+- Sarcopenic obesity prevalence in older adults: 10-20%
+- 15-40% of total weight lost on GLP-1s is lean body mass, with some analyses suggesting up to 60%
+- 64.8% of GLP-1 patients discontinue within one year
+- Next-generation GLP-1 compounds are being developed with claims to improve muscle preservation